Broadcom 38% Upside, Apple PT Hike! 02/01/26 - podcast episode cover

Broadcom 38% Upside, Apple PT Hike! 02/01/26

Feb 01, 20260
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Broadcom 38% Upside, Apple PT Hike! 02/01/26

Key Stories:

  • Bank of America Securities is projecting a significant 38% upside for Broadcom Inc., the major semiconductor and infrastructure software solutions provider. Analyst Vivek Arya recently reiterated a Buy rating on the stock, a strong vote of confidence that positions Broadcom among the most profitable NASDAQ stocks to consider right now. This positive outlook suggests continued strength in Broadcom’s core markets, making it a name investors might want to keep a close eye on for potential growth opportunities, especially given the ongoing demand for its advanced technology solutions. Read more
  • Shifting our focus to another tech giant, JPMorgan analysts are feeling much more confident about Apple Inc., the iPhone maker and global technology leader. Analyst Samik Chatterjee just raised Apple’s price target to a robust $325, while maintaining an “Overweight” rating on the stock. This move comes with the firm’s belief that Apple’s recent results should help calm any lingering investor nerves. The company is also noted as one of the significant players making waves in the AI sector, indicating its broad influence. This updated target from JPMorgan offers a positive signal for Apple’s near-term performance and reassures investors about its strategic direction. Read more
  • Moving away from pure tech, pharmaceutical giant Bristol Myers Squibb Company is also seeing a positive shift in analyst sentiment. Piper Sandler has increased its price target for Bristol Myers Squibb to $66, up from $62, and is maintaining an “Overweight” rating. The firm highlights that the stock, traded under BMY, remains undervalued even with current pricing, which largely accounts for upcoming patent expirations. This upgrade is driven by improved visibility into the company’s robust drug pipeline. For investors, this suggests that Bristol Myers Squibb could be an attractive option, potentially offering upside as the market begins to fully appreciate the value of its future product offerings and innovation in the healthcare space. Read more

Keywords: AAPL, AI Stocks, AVGO, Apple, BMY, Bank of America, Bristol Myers Squibb, Broadcom, Buy rating, JPMorgan, NASDAQ, Overweight rating, Piper Sandler, Samik Chatterjee, Vivek Arya, healthcare, iPhone, infrastructure software, investor confidence, pharmaceutical, pipeline, price target, semiconductor, stock upside, tech giant, undervalued

The post Broadcom 38% Upside, Apple PT Hike! 02/01/26 first appeared on Rapid Money Radio.

For the best experience, listen in Metacast app for iOS or Android